Denali Therapeutics Inc

NASDAQ: DNLI
$23.94
+$0.61 (+2.6%)
Closing Price on July 16, 2024

DNLI Chart and Intraday Price

DNLI Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Address 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 2,882.79M USD
Shares Outstanding 138,197,000
Denali Therapeutics Inc. is a pioneering biopharmaceutical firm focused on defeating neurodegenerative and lysosomal storage diseases. With a unique approach that involves engineering treatments to cross the blood-brain barrier, Denali is advancing a diverse portfolio. This includes therapies for conditions like Parkinson's disease, amyotrophic lateral sclerosis, and various forms of mucopolysaccharidosis. Collaborating with industry giants like Biogen and Takeda, Denali is at the forefront of developing innovative solutions for complex brain disorders. Founded in 2013, the company is based in South San Francisco, California.

DNLI Articles

Wednesday's additional analyst upgrades and downgrades included CrowdStrike, Ecolab, KKR, Microsoft, Tilray Brands and Twilio.
Monday's top analyst upgrades and downgrades included Broadcom, Costco Wholesale, DraftKings, Exxon Mobil, Foot Locker, Marvell Technology, Nvidia, Payoneer Global, Philip Morris International, Pure...
Tuesday's top analyst upgrades and downgrades included AT&T, Comcast, First Solar, Fortinet, Jefferies Financial, Next Era Energy Partners, T-Mobile and Walt Disney.
Wednesday’s top analyst upgrades and downgrades included Apple, AMC Entertainment, Facebook, First Solar, Kansas City Southern, Roku and SolarEdge.
Monday's top analyst upgrades and downgrades included Albermarle, Apple, Consolidated Edison, Etsy, GoHealth, Hecla Mining, NortonLifeLock, Pinterest, Switch and T-Mobile.